Teva to produce new biosimilar drugs outside Israel

People close to the matter revealed that Teva plans to manufacture a new biosimilar outside Israel, Globes reported Wednesday.

It was previously believed that the drugmaker would use its Kfar Saba site, which manufactures Copaxone, to produce biosimilars and complex generics.

Meanwhile, labour disputes at the site may have influenced Teva's decision to manufacture the drug outside the country.

A labour dispute was declared at the facility earlier this month after management offered staff a 1.4-percent pay increase after no pay hike in 2018.

"We have no desire to harm the company, but we will not allow the company to harm us," commented Teva Kfar Saba workers' committee chairperson Eliran Kozlik, adding "this site is more important to us than to managers who serve one or two terms. We will stay here; it is our home."